Revenue
5Y CAGR +7.0%5Y CAGR +7.0%No quarters filed for this figure.
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Bar = where today’s multiple sits in ARGX’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
FY25: operating cash flow $685.2M, capex −$6.2M
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on immunology medicines, including treatments for generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. argenx also advances a broader pipeline of differentiated antibody therapeutics built on its proprietary Simple Antibody platform, which supports research across autoimmune and other specialty disease areas. As an ADR, it gives U.S. market participants a way to access argenx’s underlying equity exposure through a familiar U.S.-traded security. The asset is closely tied to the global biotechnology and healthcare markets, where demand for specialized biologic therapies continues to shape commercial and clinical activity.
Amsterdam, Netherlands·1,599 employees·Biotechnology·argenx.com·As of Oct 28, 2026
No earnings release, press release or insider trade outside a 10b5-1 plan in the last 120 days.
All filings and insider trades →11 of the 193 ETFs ChartRow carries live hold ARGX. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| EWK | iShares MSCI Belgium ETF | 16.9% |
| IBB | iShares Biotechnology ETF | 3.8% |
| VGK | Vanguard FTSE Europe ETF | 0.3% |
| EFA | iShares MSCI EAFE ETF | 0.2% |
| VEA | Vanguard FTSE Developed Markets ETF | 0.2% |
| VEU | Vanguard FTSE All-World ex-US ETF | 0.1% |
| VXUS | Vanguard Total International Stock ETF | 0.1% |
| URTH | iShares MSCI World ETF | 0.1% |
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |